Th2a Cell Frequency Detection for Immune Disorder Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring the progress and efficacy of allergen-specific immunotherapy are limited, with a therapy duration of 3 to 5 years and variable efficacy rates, and lack accurate detection and monitoring of immune responses, particularly for immune-related disorders and allergies.
Innovation Solution
The method involves detecting the frequency of allergen-specific Th2a subset of CD4+ T cells in biological samples, using techniques like fluorescent activated cell sorting (FACS), to diagnose immune disorders and monitor immune deviation during immunotherapy, allowing for more precise treatment tailoring and prediction of therapy effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allergen-specific immunotherapy is administered for 3 to 5 years, then treatment coverage is provided, but therapy duration is excessively long and efficacy varies widely
Solution Approach 1:
The patent applies preliminary action by detecting Th2a cell frequencies before initiating immunotherapy and at regular intervals during treatment. This early detection approach allows prediction of treatment efficacy before the full 3-5 year course is completed, enabling earlier assessment and potential adjustment of therapy duration based on individual patient response rather than following a fixed timeline for all patients
Solution Approach 2:
The patent implements feedback by using Th2a cell frequency measurements as a monitoring tool throughout the immunotherapy course. The detected frequencies provide continuous feedback on immune response progression, allowing clinicians to assess whether the therapy is achieving the desired immune deviation from Th2 to Th1 response, thereby optimizing treatment duration and efficacy for each patient
2Measurement precision
If traditional monitoring methods are used, then treatment is provided, but accurate detection and monitoring of immune response is lacking
Solution Approach 1:
The patent applies the taking out principle by specifically isolating and measuring the Th2a subset of CD4+ T cells from the overall immune response. Instead of using general immune response markers, the method extracts and quantifies this specific cell population that is directly relevant to allergic responses and immunotherapy efficacy, providing precise measurement of the critical immune parameter
Solution Approach 2:
The patent replaces traditional mechanical/physical monitoring methods with immunological detection methods. Instead of relying on symptom assessment or general inflammatory markers, the method uses flow cytometry or similar techniques to detect and quantify Th2a cells based on their specific surface markers (CD4+, CRTH2+, CD161+), substituting direct immunological measurement for indirect clinical observation
Data Source
AI summary
Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+ T cells in a biological sample of said subject; (b) detecting a frequency of a Th2a subset of the CD4+ T cells in the biological sample; and (c) comparing the frequency of the Th2a subset with the frequency of the CD4+ T cells.